How can we promote good eating and a healthy body image?

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and improved treatment access.

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.